Trial Profile
Phase 1, Open-label, Single Ascending-dose Study to Assess Safety, Pharmacokinetics, Biodistribution and Radiation Dosimetry of Intravenous Doses of Alpharadin Injection (Radium-223 Chloride) in Patients With HRPC and Skeletal Metastases
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Bayer
- 23 Feb 2015 According to a Bayer HealthCare Pharmaceuticals, data from this study will be presented at the 2015 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU).
- 06 Oct 2014 New trial record